Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia

Expert Opinion on Investigational Drugs

Volumn 16, Issue 9, 2007, Pages 1425-1439

  Tiwari, Atul ^a  

^a JUBILANT BIOSYS LTD   (India)

Author keywords

BPH; GnRH modulators; Hormone modulators; Lower urinary tract symptoms; Prostate

Indexed keywords

4 [3 [3 [BIS(4 ISOBUTYLPHENYL)METHYLAMINO]BENZOYL] 1H INDOL 1 YL]BUTYRIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; BUSERELIN; CETRORELIX; CS 902; CYOCTOL; D 63153; DESLORELIN; DUTASTERIDE; EPRISTERIDE; FINASTERIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; HISTRELIN; HORMONE; LEUPRORELIN; NAFARELIN; OSATERONE; OZARELIX; PLACEBO; PROSTARINE; STEROID 5ALPHA REDUCTASE INHIBITOR; TEVERELIX; TRIPTORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE; ZANOTERONE; ZEN 019; SEX HORMONE;

AGING; ANAPHYLAXIS; BONE DENSITY; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; DEPRESSION; DRUG BIOAVAILABILITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SYNTHESIS; DRUG WITHDRAWAL; DRY SKIN; EJACULATION; EJACULATION DISORDER; ENDOMETRIOSIS; ERECTILE DYSFUNCTION; FATIGUE; FRACTURE; GYNECOMASTIA; HEART PALPITATION; HOT FLUSH; HUMAN; IMPOTENCE; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; LIBIDO; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MALE; MASTALGIA; MOOD; MOOD DISORDER; NERVE COMPRESSION; NONHUMAN; OSTEOPOROSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SMOOTH MUSCLE TONE; SPINAL CORD COMPRESSION; SYMPTOM; UNSPECIFIED SIDE EFFECT; URETER OBSTRUCTION; URETHRA OBSTRUCTION; URINARY TRACT DISEASE; URINE FLOW RATE; ANIMAL; METABOLISM; PHARMACEUTICS;

ANIMALS; GONADAL STEROID HORMONES; HUMANS; MALE; PROSTATIC HYPERPLASIA; TECHNOLOGY, PHARMACEUTICAL;

EID: 34548587664     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.9.1425     Document Type: Review

References (82)

1. MARCELLI M, CUNNINGHAM GR: Hormonal signaling in prostatic hyperplasia and neoplasia. J. Clin. Endocrinol. Metab. (1999) 84:3463-3468.
2. CAINE M: The present role of α-adrenergic blockers in the treatment of benign prostatic hypertrophy. J. Urol. (1986) 136:1-4.
3. TIWARI A, KRISHNA NS, NANDA K, CHUGH A: Benign prostatic hyperplasia: an insight into current investigational medical therapies. Expert Opin. Investig. Drugs (2005) 14(11):1359-1372.
4. GEORGE FW, CARR BR, NOBLE JF, WILSON JD: 5-α-Reduced androgens in the human fetal testis. J. Clin. Endocrinol. Metab. (1987) 64:628-630.
5. SPAN PN, SCHALKEN JA, SWEEP FG, SMALS AG: Identification and partial characterization of two steroid 5 α-reductase isozymes in the canine prostate. Prostate (1998) 34(3):222-230.
6. PELLETIER G, LUU-THE V, HUANG XF, LAPOINTE H, LABRIE F: Localization by in situ hybridization of steroid 5 α-reductase isozyme gene expression in the human prostate and preputial skin. J. Urol. (1998) 160:582-587.
7. BARTSCH G, RITTMASTER RS, KLOCKER H: Dihydrotestosterone and the concept of 5 α-reductase inhibition in human benign prostatic hyperplasia. World J. Urol. (2002) 19:413-425.
8. THOMAS LN, DOUGLAS RC, VESSEY JP et al.: 5 α-Reductase type I immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J. Urol. (2003) 170:2019-2023.
9. GLASSMAN DT, CHON JK, BORKOWSKI A, JACOBS SC, KYPRINOU N: Combined effect of terazosin and finasteride on apoptosis, cell proliferation and transforming growth factor-β expression in benign prostatic hyperplasia. Prostate (2001) 46(1):45-51.
10. STONER E: The clinical effects of a 5 α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J. Urol. (1992) 147:1298-1302.
11. BEISLAND HO, BINKOWITZ B, BREKKAN E et al.: Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. (1992) 22:271-277.
12. GORMLEY GJ, STONER E, BRUSKEWITZ RC et al.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Eng. J. Med. (1992) 327:1185-1191.
13. GRINO P, STONER E: Finasteride for the treatment and control of benign prostatic hyperplasia: summary of Phase III controlled study. The Finasteride Study Group. Eur. Urol. (1994) 25(Suppl. 1):24-28.
14. BYRNES CA, MORTON AS, LISS CL, LIPPERT MC, GILLENWATER JY: Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar. Clin. Ther. (1995) 17:956-969.
15. STONER E: Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group. Arch. Intern. Med. (1994) 154:83-88.
16. NICKEL JC, FRADET Y, BOAKE RC et al.: Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two Year Study. CMAJ(1996) 155:1251-1259.
17. WESSELLS H, ROY J, BANNOW J et al.: Incidence and severity of sexual adverse experiences in finasteride and placebo-treatea men with benign prostatic hyperplasia. Urology (2003) 61:579-584.
18. TVETER KJ, BEISLAND HO, ANDERSEN JT et al.: Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study. Tidsskr Nor Laegeforen (1996) 116:3226-3230.
19. MARTINEZ SM, CUNAT AE, LOPEZ AE et al.: Treatment of benign prostatic hyperplasia with finasteride. Results after 7 years of follow-up. Actas Urol. Esp. (1997) 21:105-110.
20. MARBERGER MJ: Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology (1998) 51:677-686.
21. HUDSON PB, BOAKE R, TRACHTENBERG J et al.: Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology (1999) 53:690-695.
22. VAUGHAN D, IMPERATO-MCGINLEY J, McCONNELL J et al.: Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology (2002) 60:1040-1044.
23. McCONNELL JD, BRUSKEWITZ R, WALSH P et al: The effect of finasteride on the risk of urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N. Eng. J. Med. (1998) 338(9):557-563.
24. BRUSKEWITZ R, GIRMAN CJ, FOWLER J A et al.: Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology (1999) 54:670-678.
25. ROEHERBORN CG, BRUSKEWITZ R, NICKEL GC et al.: Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study. Eur. Urol. (2000) 37:528-536.
26. KAPLAN S, GARVIN D, GILHOOLY P et al.: Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-retated outcomes and long-term response to finasteride. The Pless Study Group. Urology (2000) 56:610-616.
27. MATSUMOTO AM, TENOVER L, MCCLUNG M et al.: The long-term effect of specific type II 5 α-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J. Urol. (2002) 167:2105-2108.
28. RAHIMI-ARDABILI B, POURANDARJANI R, HABIBOLLAHI P, MUALEKI A: Finasteride induced depression: a prospective study. BMC Clin. Pharmacol. (2006) 7:6-7.
29. ROEHERBORN CG, BOYLE P, NICKEL JC et al.: Efficacy and safety of dual inhibitor of 5-α-reductase types 1 and 2 (Dutasteride) in men with benign prostatic hyperplasia. Urology (2002) 60:434-441.
30. ANDRIOLE GL, KIRBY R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. (2003) 44:82-88.
31. LEPOR H, WILLIFORD WO, BARRY MJ et al.; FOR THE VETERANS AFFAIRS COOPERATIVE STUDIES BENIGN PROSTATIC HYPERPLASIA STUDY GROUP: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N. Eng. J. Med. (1996) 335:533-539.
32. KIRBY R, BOYLE P, ROEHRBORN C: Result of PREDICT (Prospective Randomized European Doxazosin and Combination) study of medical therapy for BPH. Br. J. Urol. (1999) 83:83 (Abstract).
33. CALAIS DA SILVA F, MARQUIS P DESCHASEAUX P, GINESTE JL, CAUQUIL J, PATRICK DL: Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur. Urol. (1997) 31:272-280.
34. SUN ZY, FENG J, QUI XD, WU HY, ZHENG WJ, TU ZH: Reversible long-term toxicity of epristeride in beagle dogs. Toxicol. Appl. Pharmacol. (1999) 154(2):145-152.
35. THOMPSON IM, GOODMAN PJ, TANGEN CM et al.: The influence of finasteride on the development of prostate cancer. N. Eng. J. Med. (2003) 349:215-224.
36. REYNOLDS T: Prostate cancer prevention trial yields positive results, but with a few cautions. J. Natl. Cancer Inst. (2003) 95:1030-1031.
37. BERREVOETS CA, UMAR A, BRINKMANN AO: Antiandrogens: selective androgen receptor modulators. Mol. Cell Endocrinol. (2002) 198:97-9103.
38. BERGER BM, NAADIMUTHU A, BODDY A et al.: The effect of zanosterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. The Zanosterone Study Group. J. Urol. (1995) 154:1060-1064.
39. SCHALLY AV: Hypothalamic hormones from neuro-endocrinology to cancer therapy. Anticancer Drugs (1994) 5:115-130.
40. STANISLAUS D, PINTER JH, JANOVICK JA, CONN PM: Mechanisms mediating multiple physiological responses to gonadotropin-releasing hormone. Mol. Cell Endocrinol. (1998) 144:1-10.
41. MILLAR RP, LU Z, PAWSON AJ et al.: Gonadotropin-releasing hormone receptors. Endocrine. Rev. (2005) 25:235-275.
42. FINK G: Gonadotropin secretion and its control. In: The Physiology of Reproduction, Knobil E, Neill J (Eds), Raven Press, New York, USA (1988):1349-1377.
43. STOJILKOVIC SS, REINHART J, CATT KJ: Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr. Rev. (1994) 15:462-499.
44. KAISER UB, CONN PM, CHIN WW: Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr. Rev. (1997) 18:46-70.
45. CONN PM, CROWLEY WF Jr: Gonadotropin-releasing hormone and its analogs. Ann. Rev. Med. (1994) 45:391-405.
46. KARTEN MJ, RIVIER JE: Gonadotropin-releasing hormone analog design-structure-function studies towards the development of agonists and antagonists: rationale and perspective. Endocr. Rev. (1986) 7:44-66.
47. SCHLEGEL PN, BRENDLER CB: Management of urinary retention due to benign prostatic hyperplasia using lutenizing hormone-releasing hormone agonist. Urology (1989) 34:69-72.
48. BOSCH RJ, GRIFFITHS DJ, BLOM JH, SCHROEDER PH: Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J. Urol. (1989) 141:68-72.
49. OESERLING JE: LHRH agonists: a nonsurgical treatment for benign prostatic hyperplasia. J. Androl. (1991) 12:381-388.
50. ERI LM, TVETER KJ: A prospective, placebo-controlled study of the lutenizing hormone-releasing agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J. Urol. (1993) 150:359-364.
51. PALLAS P, PARADA G: Treatment of acute urinary retention caused by benign prostatic hypertrophy with an LH-RH agonist (goserelin). Actas Urol. Esp. (1995) 19:118-122.
52. GABRILOVE JL, LEVINE AC, KIRSCHENBAUM A, DROLLER M: Effects of a GnRH analogue (leuprolide) on benign prostatic hypertrophy. J. Clin. Endocrinol. Metab. (1987) 64:1331-1333.
53. ERI LM, HAUQ E, TVETER KJ: Effects on the endocrine system of long-term treatment with the lutenizing hormone releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia. Scand. J. Clin. Lab. Invest. (1996) 56:319-325.
54. CROOK T, SHERIDAN WP: Development of GnRH antagonists for prostate cancer: new approaches to treatment. Ontologist (2000) 5:162-168.
55. WILLIAMS MB, HERNANDEZ J, THOMPSON I: Lutenizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J. Urol. (2005) 173(4):1067-1071.
56. EVANS CP, FLESHNER N, FITZPATRICK JM, ZLOTTA AR: An evidence-based approach to understanding the pharmacological class cffect in die management of prostatic diseases. BJU Int. (2005) 95:743-749.
57. HUIRNE JA, LAMBALK CB: Gonadocropin-releasing-hormone-receptor antagonists. Lancet (2001) 358:1793-1803.
58. WECKERMANN D, HARZMANN R: Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur. Urol. (2004) 46:279-284.
59. TARLATZIS BC, BILI H: Safety of GnRH agonists and antagonists. Expert Opin. Drug Saf. (2004) 3(1):39-46.
60. KIESEL L, THOMAS K, TEMPONE A et al.: Efficacy and safety of buserelin treatment in women with endometriosis-a multicentre open-label study. Gynecol. Endocrinol. (1989) 3(Suppl. 2):5-19.
61. GIULIANI A, SCHOELL W, AUNER J, URDL W: Controlled ovarian hyper-stimulation in assisted reproduction: effect on the immune system. Fertil. Steril. (1998) 70:831-835.
62. GONZALEZ-BARCENA D, VADILLO-BUENFIL M, GOMEZ-ORTA F et al.: Responses to the antagonistic analog of LH-RH SB-75, cetrorelix in patients with benign prostatic hyperplasia and prostatic cancer. Prostate (1994) 24:84-92.
63. COMARU-SCHALLY AM, BRANNAN W, SCHALLY AV, COLCOLOUGH M, MONGA M: Efficacy and safety of lutenizing hormone-releasing antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. (1998) 83:3826-3831.
64. DEBRUYNE FMJ, TZVETKOV M, MEDVEREC Z et al.: Cetrorelix pamoate, an LHRH antagonist, in the treatment of BPH: randomized, placebo-controlled multicenter study. In: The 28th Congress of the Societe Internationale d'Urologie, (12-16 November 2006), Cape Town, South Africa. (Abstract).
65. JIANG G, GAVINI E, DANI BA et al.: Identification and determination of GnRH anatagonist gelling at injection site. Int. J. Pharmaceut. (2002) 233:19-27.
66. EMONS G, GRÜNDKER C, GÜNTHERT AR, WESTPHALEN S, KARANAGH J, VERSCHRAEGEN C: GnRH antagonists in the treatment of gynecological and breast cancers. Endocri. Rel. Cancer (2003) 10:291-299.
67. MAUDSLEY S, DAVIDSON L, PAWSON AJ, CHAN R, DE MATURANA RL, MILLER RP: Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Gαi-coupled state of the type I GnRH receptor. Cancer Res. (2004) 64(20):7533-7544.
68. WHITTINGTON K, ASSINDER S, GOULD M, NICHOLSON H: Oxytocin-associated neurophysin and the oxytocin receptor in the human prostate. Cell Tissue Res. (2004) 318:375-382.
69. NICHOLSON HD: Oxytocin: a paracrine regulator of prostatic function. Rev. Reprod. (1996) 1:69-72.
70. REVERSI A, RIMOLDI V, MORROCCO T et al.: The oxytocin receptor antagonist atosiban inhibits cell growth via a 'biased agonist' mechanism. J. Biol. Chem. (2005) 280:16311-16318.
71. ZHANG XH, FILLIPI S, VIGNOZZI L et al.: Identification, localization and functional in vitro and in vivo activity of oxytocin receptor in the rat penis. J. Endocrinol. (2005) 184:567-576.
72. GLIENKE W, DOLGOVA Y, MULLER I et al.: Induction of apoptosis in human prostate stromal cells by 4-hydroxytamoxifen: an alternative therapy for benign prostatic hyperplasia. World J. Urol. (2004) 22:452-456.
73. HABENICHT UF, TUNN UW, SENGE T et al.: Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J. Steroid Biochem. Mol. Biol. (1993) 44:557-563.
74. GINGELL JC, KNONAGEL H, KURTH KH, TUNN UW; THE SCHERING 90,062 STUDY GROUP: Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. J. Urol. (1995) 154:399-401.
75. McPHERSON SJ, ELLEM SJ, SIMPSON ER, PATCHEV V, FRITZEMEIR KH, RISBRIDGER GP: Essential role for estrogen receptor β in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology (2007) 148:566-574.
76. PEEHL DM, SKOWRONSKI RJ, LEUNG GK, WONG ST, STAMEY TA, FELDMAN D: Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. (1994) 54:805-810.
77. SKOWRONSKI RJ, PEEHL DM, FELDMAN D: Vitamin D and prostate cancer. 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology (1993) 132:1952-1960.
78. WU-WONG JR, TIAN J, GOLTZMAN D: Vitamin D analogs as therapeutic agents: a clinical study update. Curr. Opin. Investig. Drugs (2004) 5:320-326.
79. STONER E: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology (1994) 43:284-289.
80. CRESCIOLI C, MORELLI A, ADORINI L: Human bladder as a novel target for vitamin D receptor ligands. J. Clin. Endocrinol. Metab. (2005) 90:962-972.
81. TIWARI A, NARUGANAHALLI NS: Current and emerging investigational medical therapies for the treatment of overactive bladder. Expert Opin. Investig. Drugs (2006) 15(9):1017-1037.
82. MCCONNELL JD, ROEHERBORN CG, BAUTISTA OM et al.: The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. (2003) 349:2387-2398.